HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

Item

http://www.wikidata.org/entity/Q36326779

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@ast

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@en

type

Item

label

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@ast

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@en

prefLabel

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@ast

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@en

P1476

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

@en

P2093

Berenice Avalos

http://www.w3.org/2001/XMLSchema#string

Blanca Segura-Pacheco

http://www.w3.org/2001/XMLSchema#string

Dora Velazquez

http://www.w3.org/2001/XMLSchema#string

Edgar Rangel

http://www.w3.org/2001/XMLSchema#string

Gustavo Cabrera

http://www.w3.org/2001/XMLSchema#string

P2860

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Identification of alternative splice products encoded by the human coxsackie-adenovirus receptor gene

Clinical development of histone deacetylase inhibitors as anticancer agents

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Development and application of adenoviral vectors for gene therapy of cancer.

P2888

1479-0556-5-10

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-0556-5-10

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5951226

http://www.w3.org/2001/XMLSchema#string

P6179

1042586235

http://www.w3.org/2001/XMLSchema#string

P698

17892546

http://www.w3.org/2001/XMLSchema#string

P932

2174455

http://www.w3.org/2001/XMLSchema#string